Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123618 | 0.80 | MCHR1 (0.32) | MCHR1CCND1CDK6CDK4 | |
| SCHEMBL5838366 | 0.78 | KDM4E (0.53) | KDM4EGAARAB9A | |
| SCHEMBL5838404 | 0.78 | KDM4E (0.41) | KDM4EGAARAB9A | |
| SCHEMBL4707651 | 0.78 | KDM4E (0.32) | MCHR1KDM4ERAB9A | |
| SCHEMBL5837975 | 0.74 | KDM4E (0.57) | KDM4EGAARAB9A | |
| SCHEMBL7125950 | 0.73 | MCHR1 (0.35) | MCHR1RAB9A | |
| SCHEMBL7121125 | 0.73 | EGFR (0.57) | — | |
| SCHEMBL7127856 | 0.73 | PDE10A (0.40) | MCHR1KDM4EGLAGAARAB9A | |
| SCHEMBL7122716 | 0.72 | MCHR1 (0.33) | MCHR1CCND1CDK6CDK4 | |
| SCHEMBL5241545 | 0.72 | MCHR1 (0.31) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | MCHR1 3278/4885CCND1 14/4885KDM4E 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.